Advancing Intelligent Horizons Towards Brain Health
CINP-AsCNP 2025 Joint Congress

With the development of science and technology in recent years, efforts to apply neuropsychopharmacology to clinical practice in neuropsychiatric disorders have flourished worldwide. There have been many important developments within Australia, which has developed a youth mental health paradigm and clinical staging for early psychosis including at risk states. Moreover, Australia is the first country to permit the use of psilocybin assisted therapy for treatment resistant depression and MDMA assisted therapy for post-traumatic stress disorder (July 2023) and has also pioneered trials in psilocybin assisted therapy for generalised anxiety disorder.

CINP-AsCNP2025 will bring together experts from research and medical institutions, leading worldwide regulatory authorities and major pharmaceutical firms to promote basic and clinical research and to create a framework for a cohesive collaboration between academia, industry and governmental institutions toward the development and appropriate use of central nervous system drugs. We are confident that, by fostering discussion between world leaders in neuropsychopharmacology and international expertise in related fields, the congress will lead directly to innovative developments in a wide range of fields associated with central nervous system drugs.
We invite you to be part of these discussions and to play your part in the development of our field!